Wednesday, February 10, 2010, 11:06pm SGT - The Singapore stock market is closed.
To create a watchlist or portfolio of shares, Register
FINANCE HOME PAGEINVESTINGFINANCE NEWS
    Market:       |  

Ariad Pharmaceuticals Inc. (ARIA)

At 10:51PM SGT: 2.28 USD  Down 0.07 (2.98%)  
 MORE ON ARIA 
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
 ARIAD Pharmaceuticals, Inc. (NGM:ARIA) Delayed quote dataEdit
Last Trade:2.28 USD
Trade Time:10:51PM SGT
Change:Down 0.07 (2.98%)
Prev Close:2.35
Open:2.32
Bid:2.28 x 5700
Ask:2.29 x 2500
1y Target Est:5.00
Day's Range:2.28 - 2.35
52wk Range:0.97 - 3.48
Volume:120,864
Avg Vol (3m):1,958,730
Market Cap:248.42M
P/E (ttm):N/A
EPS (ttm):-0.94
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
Use Y! Toolbar to track stocks
 Add ARIA to Portfolio   Download Data

 HEADLINES 
•ARIAD to Present at the 12th Annual BIO CEO & Investor Conference
Business Wire (Thu, Jan 28)
•ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
EDGAR Online (Sat, Jan 23)
•ARIAD to Present at the 28th Annual J.P. Morgan Healthcare Conference
Business Wire (Mon, Jan 4)
•Top Ten '09 Clone Portfolios
at Seeking Alpha (Sun, Jan 3)
•5 Cold Stocks Heating Up
at Motley Fool (Tue, Dec 29)
•This Year's Upside Crash & 3 PowerRatings Stocks
TradingMarkets.com (Mon, Dec 21)
•Friday Options Update: SVNT, JBLU, ROST, RVSN, MRVL, RYL, ARIA, WLP
at Seeking Alpha (Sat, Dec 19)
•Friday Options Update: MRVL, RYL, ARIA, WLP
at Seeking Alpha (Sat, Dec 19)
•Ariad rounds out phase 3 cancer study
at bizjournals.com (Fri, Dec 18)
•ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Fri, Dec 18)
•ARIAD Announces Full Enrollment in Phase 3 Succeed Trial Evaluating Ridaforolimus in Patients with Metastatic Sarcomas
Business Wire (Thu, Dec 17)
•ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
EDGAR Online (Wed, Dec 16)
•ARIAD Announces Updated Data from Clinical Trial of Its Investigational mTOR Inhibitor, Ridaforolimus, In Combination with Trastuzumab
Business Wire (Mon, Dec 14)
More Headlines for ARIA...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.84
EPS Est (in 2 years) (Dec-10) :-0.63
Avg Rec (current)*:1.4
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
ARIAD Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer in the United States and Europe.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Search by Company
•Latest News•Singapore Indices